Amendment No. 7 to Letter of Intent for Proposed CRADA #2166 between National Cancer Institute and NewLink Genetics Corporation
This amendment extends the term of the Letter of Intent for the proposed Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute (NCI) and NewLink Genetics Corporation. The agreement, focused on preclinical and clinical development, is extended by six months, now ending on May 23, 2011. All other terms of the original Letter of Intent remain unchanged. Both parties have signed the amendment to confirm their acceptance of these changes.
Exhibit 10.45
AMENDMENT #7
To Letter of Intent for Proposed CRADA #2166
“Preclinical and Clinical Development of [*]”
The purpose of this Amendment is to change certain terms of the Letter of Intent (LOI) for the proposed Cooperative Research and Development Agreement (CRADA) entitled “Preclinical and Clinical Development of [*].” These changes are reflected below, and except for these changes, all other provisions of the original CRADA LOI remain in full force and effect. Two originals of this Amendment are provided for execution; one is to remain with the National Cancer Institute (NCI) and the other original is to remain with the Collaborator.
Upon final signature, the term of the CRADA Letter of Intent is extended for six months from November 23, 2010 to, May 23, 2011.
| ACCEPTED AND AGREED TO: |
|
|
|
|
|
|
| For the National Cancer Institute: |
|
|
|
|
|
|
|
|
|
|
| /s/ Douglas R. Lowy |
| 11/26/10 |
| Douglas R. Lowy, M.D. |
| Date |
| Deputy Director, NCI |
|
|
|
|
|
|
|
|
|
|
| For NewLink Genetics Corporation: |
|
|
|
|
|
|
|
|
|
|
| /s/ Nicholas Vahanian |
| 1/12/10 |
| Nicholas Vahanian, M.D. |
| Date |
| Chief Operating Officer |
|
|
